|
CN111671731A
|
|
Quick-release preparation containing milnacipran hydrochloride and preparation method thereof
|
|
CN110963916A
|
|
Preparation method of 2- (acetoxyethyl) cyclohexanone
|
|
CN108658939A
|
|
A kind of synthetic method of dabigatran etexilate methanesulfonate key intermediate
|
|
CN108658938A
|
|
A kind of synthetic method of dabigatran etexilate methanesulfonate process contaminants
|
|
CN109422722A
|
|
A kind of preparation method of benzothienyl compounds intermediate
|
|
CN109206323A
|
|
A kind of preparation method of naphthylamines pharmaceutical intermediate
|
|
CN108264533A
|
|
A kind of Preparation Method And Their Intermediate of Austria's shellfish cholic acid
|
|
CN108264532A
|
|
A kind of Preparation Method And Their Intermediate of Austria's shellfish cholic acid
|
|
CN106389428A
|
|
Composition capable of improving Azilsartan bioavailability and stability and preparation method of composition
|
|
CN107337664A
|
|
One koji Ge Lieting preparation method
|
|
CN105561326A
|
|
Trelagliptin clathrate, preparation method and application thereof
|
|
CN106928124A
|
|
The preparation method of onglyza intermediate
|
|
CN105418614A
|
|
New crystal form of ticagrelor as well as preparation method and application thereof
|
|
CN106810485A
|
|
A kind of Preparation Method And Their Intermediate of chiral boxidine alkanone
|
|
CN104230978A
|
|
Preparation midbody for Ezetimibe and preparation method of preparation midbody
|
|
CN104058992A
|
|
Crystal form of levomilnacipran hydrochloride
|
|
CN103694237A
|
|
Preparation method and key intermediate of anticoagulant apixaban
|
|
CN103739541A
|
|
Preparation method of 5,6-dihydro-3-(4-morpholinyl)-1-[4-(2-oxy-1-piperidyl) phenyl]-2(1H)-pyridone
|
|
CN103694162A
|
|
Preparation method of (1S, 2R)-1-phenyl 2-(phthalimide) methyl-N, N-diethyl-cyclopropanecarboxamide
|
|
CN103613513A
|
|
Milnacipran hydrochloride intermediate as well as preparation method and application thereof
|
